Amgen, Inc. (AMGN) Shares Bought by Verity & Verity LLC

Verity & Verity LLC increased its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 3.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 18,787 shares of the medical research company’s stock after buying an additional 683 shares during the period. Verity & Verity LLC’s holdings in Amgen were worth $3,894,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in AMGN. Beutel Goodman & Co Ltd. purchased a new stake in Amgen during the second quarter worth about $86,723,000. Natixis boosted its holdings in Amgen by 2,612.1% during the second quarter. Natixis now owns 529,816 shares of the medical research company’s stock worth $97,799,000 after buying an additional 510,281 shares in the last quarter. Summit Trail Advisors LLC boosted its holdings in Amgen by 16,458.8% during the first quarter. Summit Trail Advisors LLC now owns 433,510 shares of the medical research company’s stock worth $434,000 after buying an additional 430,892 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Amgen by 17.0% during the second quarter. Dimensional Fund Advisors LP now owns 2,365,045 shares of the medical research company’s stock worth $436,551,000 after buying an additional 343,690 shares in the last quarter. Finally, Bank of Nova Scotia boosted its holdings in Amgen by 234.2% during the second quarter. Bank of Nova Scotia now owns 433,450 shares of the medical research company’s stock worth $80,011,000 after buying an additional 303,743 shares in the last quarter. 82.48% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:AMGN opened at $202.77 on Thursday. The company has a quick ratio of 3.12, a current ratio of 3.39 and a debt-to-equity ratio of 2.03. The company has a market capitalization of $134.17 billion, a PE ratio of 16.12, a PEG ratio of 2.02 and a beta of 1.40. Amgen, Inc. has a 1-year low of $163.31 and a 1-year high of $210.19.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, July 26th. The medical research company reported $3.83 earnings per share for the quarter, beating analysts’ consensus estimates of $3.52 by $0.31. The business had revenue of $6.06 billion during the quarter, compared to analyst estimates of $5.73 billion. Amgen had a net margin of 10.19% and a return on equity of 43.18%. The company’s revenue was up 4.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.27 earnings per share. Research analysts anticipate that Amgen, Inc. will post 13.96 earnings per share for the current fiscal year.

Several analysts have issued reports on AMGN shares. JPMorgan Chase & Co. upped their price target on shares of Amgen from $191.00 to $192.00 and gave the company a “neutral” rating in a report on Friday, July 27th. BidaskClub raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a report on Wednesday, July 11th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $200.00 price target on shares of Amgen in a report on Monday, July 16th. Zacks Investment Research raised shares of Amgen from a “hold” rating to a “buy” rating and set a $207.00 price target on the stock in a report on Tuesday, June 26th. Finally, Morgan Stanley upped their price target on shares of Amgen from $210.00 to $212.00 and gave the company an “overweight” rating in a report on Thursday, October 11th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $204.90.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Featured Story: Penny Stocks

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply